Contrasting Cadrenal Therapeutics (NASDAQ:CVKD) and Adhera Therapeutics (OTCMKTS:ATRX)

Cadrenal Therapeutics (NASDAQ:CVKD) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Cadrenal Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 11.4, meaning that its stock price is 1,040% more volatile than the S&P 500.

Institutional & Insider Ownership

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Cadrenal Therapeutics and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Adhera Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for Cadrenal Therapeutics and Adhera Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1	0	1	0	2.00
Adhera Therapeutics	0	0	0	0	0.00

Cadrenal Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 176.60%. Given Cadrenal Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than Adhera Therapeutics.

Earnings & Valuation

This table compares Cadrenal Therapeutics and Adhera Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24 million	($5.63)	-0.83
Adhera Therapeutics	N/A	N/A	N/A	($1.15)	N/A

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Adhera Therapeutics beats Cadrenal Therapeutics on 5 of the 9 factors compared between the two stocks.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.